Effect of levetiracetam on epileptiform discharges in human neocortical slices

Epilepsia

Volumn 43, Issue 12, 2002, Pages 1480-1487

  Gorji, Ali ^a   Höhling, Jorg Michael ^a   Madeja, Michael ^a   Straub, Heidrun ^a   Köhling, Rüdiger ^a   Tuxhorn, Ingrid ^b   Ebner, Alois ^b   Wolf, Peter ^b   Panneck, H W ^c   Behne, F ^c   Lahl, Rainer ^d   Speckmann, Erwin Joseph ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b EPILEPSY CENTER BETHEL   (Germany)

^c Klinik fur Neurochirurgie   (Germany)

^d Institut fur Neuropathologie   (Germany)

Author keywords

Anticonvulsant drugs; Cortex; Intractable epilepsy; Seizure

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; BICUCULLINE; ETIRACETAM; MAGNESIUM ION;

ADOLESCENT; ADULT; AMPLITUDE MODULATION; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN SLICE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ELECTRIC POTENTIAL; EPILEPSY; EPILEPTIC DISCHARGE; EVOKED RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INFANT; MALE; NEOCORTEX; NEUROSURGERY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; BICUCULLINE; CHILD; CHILD, PRESCHOOL; CULTURE MEDIA; CULTURE TECHNIQUES; ELECTRIC STIMULATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; EVOKED POTENTIALS; FEMALE; HUMANS; INFANT; MAGNESIUM; MALE; MIDDLE AGED; NEOCORTEX; PIRACETAM;

EID: 18744383909     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2002.23702.x     Document Type: Article

References (35)

1. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: A model to study the effects of antiepileptic drugs: Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25:225-30.
2. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
3. Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 2000;42:89-95.
4. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-86.
5. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-83.
6. Krauss GL, Bergin A, Kramer RE, et al. Suppression of posthypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;56:411-2.
7. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001;10:287-93.
8. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206.
9. Gower AJ, Noyer M, Verloes R, et al. Ucb L059, a novel anticonvulsant drug: Pharmacological profile in animals. Eur J Pharmacol 1992;222:193-203.
10. Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232:147-58.
11. Birnstiel S, Wulfert E, Beck SG. Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch Pharmacol 1997;356:611-8.
12. Margineanu D, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000;42:281-5.
13. Gorji A, Scheller D, Straub H, et al. Spreading depression in human neocortical slices. Brain Res 2001;906:74-83.
14. Margineanu DG, Wulfert E. Ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Eur J Pharmacol 1995;286:321-5.
15. A receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br J Pharmacol 1997;122:1146-50.
16. Doheny HC, Ratnaraj N, Whittington MA, et al. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 1999;34:161-8.
17. McCormick DA. GABA as an inhibitory neurotransmitter in human cerebral cortex. J Neurophysiol 1989;62:1018-27.
18. Hwa GG, Avoli M, Oliver A, et al. Bicuculline-induced epileptogenesis in the human neocortex maintained in vitro. Exp Brain Res 1991;83:329-39.
19. Sills GJ, Leach JP, Fraser CM, et al. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 1997;325:35-40.
20. Rigo JM, Hans G, Nguyen L, et al. The antiepileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol (in press).
21. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995;286:137-46.
22. A antagonists in hypothalamic neurones. Neuropharmacology 2002:42:34-52.
23. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5-8.
24. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.
25. Saransaari P, Oja SS. Taurine release modified by GABAergic agents in hippocampal slices from adult and developing mice. Amino Acids 2000;18:17-30.
26. Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: Extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 2001;133:867-74.
27. o in the human epileptogenic neocortex maintained in vitro. Brain Res 1987;417:199-203.
28. Tancredi V, Hwa GG, Zona C, et al. Low magnesium epileptogenesis in the rat hippocampal slice: Electrophysiological and pharmacological features. Brain Res 1990;511:280-90.
29. Fraser CM, Sills GJ, Forrest G, et al. Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol 1999;126:1634-8.
30. Straub H, Köhling R, Hohling J, et al. Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 2001;44:155-65.
31. Lucke A, Musshoff U, Kohling R, et al. Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy. Br J Pharmacol 1998;124:370-6.
32. Heinemann U, Dreier J, Leschinger A, et al. Effects of anticonvulsant drugs on hippocampal neurons. Hippocampus 1994;4: 291-6.
33. Schwartzkroin PA, Haglund MM. Spontaneous rhythmic synchronous activity in epileptic human and normal monkey temporal lobe. Epilepsia 1986;27:523-33.
34. Köhling R, Lucke A, Straub H, et al. Spontaneous sharp waves in human neocortical slices excised from epileptic patients. Brain 1998;121:1073-87.
35. Straub H, Hohling JM, Kohling R, et al. Effects of nifedipine on rhythmic synchronous activity of human neocortical slices. Neuroscience 2000;100:445-52.